What Changed in ISO 10993-6:2026 and What It Means for Your Implant Studies

ISO 10993-6:2026 was published in April 2026, replacing the third edition from 2016. If you're running implantation studies or reviewing biocompatibility data packages right now, this is the version that applies.

The changes aren't cosmetic. Several of them close gaps that have caused inconsistent study design and confusing regulatory submissions for years. This article covers what changed and what it means practically for manufacturers, CROs, and regulatory affairs teams.

What the Standard Covers

ISO 10993-6 specifies requirements for implantation test methods used in the preclinical assessment of local effects after implantation. It applies to solid and non-solid materials — porous materials, liquids, gels, pastes, powders, and particulates — as well as absorbable, degradable, non-absorbable, and tissue-engineered medical products.

The standard does not address systemic toxicity, carcinogenicity, genotoxicity, or reproductive toxicity. Those are handled by other parts of the ISO 10993 series. ISO 10993-6 is specifically about local tissue response at the implant site.

Change 1: Formal Control Definitions and a New Control Selection Section

The 2016 edition didn't formally define the difference between a comparative control and a reference control. The 2026 edition does.

Comparative control: a medical device or material with a history of safe clinical use, used as a point of comparison for a new device seeking regulatory approval.

Reference control: a material with known properties considered to be generally inert in terms of biological local tissue effects, established on a historical basis within a pharmacopeia or similar standard — the most common example being HDPE.

Beyond the definitions, ISO 10993-6:2026 added Section 4.3, an entire dedicated subclause on control selection that wasn't in the previous edition. The key requirements:

• For non-absorbable devices, a comparative control shall be used

• Geometric and physical characteristics of the control should match the test article as closely as practical

• Any deviations must be documented and justified

• When a comparative control is used, reference materials from ISO 10993-12:2021 are typically also included as a procedural check

• If no appropriate comparative control exists, a reference control may be used — with documentation and justification

• The choice of control shall always be documented and justified, including if no control or a sham control is used

This formalizes what good practice already looked like in well-designed studies but creates a clear standard expectation where inconsistency existed before.

Change 2: Smaller Compositionally Representative Samples and Coupons

The 2026 edition added a formal definition for coupon: multiple smaller compositionally representative portions of a more complex or larger device that together contain all materials, surface finishes, and processing as the final finished device.

The corresponding provision in Section 4.2.2 clarifies that smaller test samples or coupons are appropriate when the medical device cannot be tested as-is due to size or complex geometry.

Requirements for coupons:

• Must contain all tissue-contacting materials and surface finishes as in the final finished device

• For devices with multiple materials, implanted samples should be of similar composition and surface finish to the final product

• With multiple materials, it can be necessary to implant several coupons together, each containing a subset of device materials

• Potential synergies and interactions between different materials in the final product should be considered

This is practically significant for complex devices — combination products, multi-material implants, devices with specialized coatings — where testing the whole device as-is isn't feasible in an animal model. Having formal language in the standard to support and define this approach strengthens the scientific justification for coupon-based study designs.

Change 3: Expanded Lymph Node Assessment Guidance

The 2016 edition mentioned lymph node assessment but the 2026 edition expands on it meaningfully, both in the main text and in the new Annex G.

The current requirements:

For non-absorbable materials: regional draining lymph nodes should be collected, evaluated macroscopically, and fixed for possible future microscopic evaluation. Macroscopic alterations require microscopic examination.

For absorbable or degradable materials: regional draining lymph nodes should be collected and microscopically evaluated — a stronger requirement reflecting the potential for degradation products to migrate to lymphoid tissue.

The standard also acknowledges a practical difficulty: regional draining lymphoid tissues can be hard to locate due to their small size and surrounding adipose tissue. The end user is cautioned to select draining lymphoid tissue based on published information for the specific species and implant location. Annex G notes that techniques such as lymphoid tissue-revealing solution can assist with identification.

This expanded guidance reflects growing recognition that particulate migration and immune responses in lymphoid tissue can be a meaningful indicator of systemic biological effects, particularly for degradable and novel materials.

Change 4: New Annex E — Peripheral Nerve Tissue

The 2016 edition had normative annexes for subcutaneous tissue, muscle, bone, and neural tissue (central nervous system and dura). The 2026 edition adds Annex E, an informative annex on test methods for devices contacting peripheral nerve tissue.

Peripheral nerve implantation differs in several important ways from CNS implantation:

• Peripheral nerve injury can manifest as pressure sores, sensorimotor deficits, or autotomy (loss of toenails or toes in rodents), requiring specific monitoring throughout the study

• Sex differences in neurophysiology can be relevant — for example, documented sex-based differences in cardiovascular effects of vagus nerve stimulation — and both sexes should be represented equally unless justified otherwise

• Test and control samples can sometimes be implanted in the same animal (e.g., contralateral sciatic nerve), but bilateral implantation may not be feasible depending on nerve function (bilateral vagus nerve implantation can disrupt cardiac, digestive, and respiratory function)

• Evaluation includes nerve segments proximal and distal to the implant, and for absorbable materials, associated ganglia should be considered for collection to assess axonal transport or degradation product migration

• Specific biomarkers for peripheral nerve assessment are identified, including neurofilament protein (NFP) for axonal integrity and S100 or MMP9 for Schwann cell morphology

Annex E applies to devices such as peripheral nerve stimulators, nerve wraps, and similar implants. As this device category has grown, the lack of specific guidance in the standard was a practical gap. The new annex provides a structured framework where previously manufacturers and CROs were working from first principles or device-specific literature alone.

Change 5: New Annex G — Microscopic Evaluation of Tissue Responses

The most substantive addition is Annex G, a new informative annex on microscopic evaluation of tissue responses to implanted materials. The 2016 edition provided scoring tables in what is now Annex F but lacked broader guidance on how to conduct and interpret the microscopic evaluation itself.

Annex G addresses:

Tissue section preparation — guidance on when to leave soft implants in place for paraffin processing versus when to remove hard implants, and when hard resin-based processing is required (for hard porous implants, bone implantation sites, absorbable implants that are hard before absorption begins)

Implant-tissue interface evaluation — the scoring systems in Annex F are suggested, not mandatory, and the pathologist is responsible for selecting appropriate terminology and justifying the scoring approach. The standard explicitly notes that terms like "minimal," "mild," "moderate," and "severe" vary between pathologists, making inter-study comparisons difficult and frequently generating regulatory requests for clarification

Control selection for scoring — reinforcing that the selected control should be a commercially available marketed implant (not recalled in any country) with well-established clinical history when possible; HDPE can be used when no adequate clinical comparator exists, but the physical differences between HDPE and the test article must be considered when interpreting results

Lymph node assessment — covered in G.5 (detailed above)

Degradation assessment — guidance on evaluating and scoring absorption of absorbable or degradable implants, including when digitalization or semi-automated image analysis may be warranted beyond histopathological scoring

Images — representative microscopic images of test and control implant sites are expected by study sponsors and regulatory agencies at each study interval; some agencies require them

Terminology Updates

The 2026 edition updated tissue and pathological terminology throughout the document. This affects how findings are described in study reports, and the standard now references the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) terminology for toxicological pathology as a resource, while noting that INHAND wasn't directly designed for local biocompatibility evaluation and adaptations may be needed.

What This Means for Studies Underway or Planned

If you have implantation studies completed under ISO 10993-6:2016, those studies don't automatically need to be repeated. The question is whether the data they generated remains adequate to support your biocompatibility conclusions under the current evaluation framework.

For studies planned now or in the near future, the 2026 edition applies. Practically, the most immediate implications are:

• Control selection rationale needs to be explicitly documented per Section 4.3, including justification for the type of control chosen and any geometric or physical mismatches

• Complex devices that previously used whole-device testing should evaluate whether a coupon-based approach is more appropriate and document that decision

• Lymph node collection planning needs to be built into the study protocol upfront, with appropriate collection and evaluation requirements based on whether the material is absorbable or non-absorbable

• Peripheral nerve device studies now have an annex to reference and should be designed to its guidance

• Pathology reports should reflect the Annex G guidance on interface evaluation, image requirements, and degradation scoring

Medical Device Consulting for ISO 10993-6:2026 Compliance

Keeping implantation study designs current with ISO 10993-6:2026 while ensuring data supports FDA review requires detailed knowledge of both the standard and regulatory expectations.

At JL Tox Consulting, we help manufacturers and CROs design studies, evaluate existing data packages, and prepare biocompatibility submissions under current ISO 10993 requirements.

Our services include:

• Implantation study design aligned with ISO 10993-6:2026, including control selection and coupon justification

• Gap analysis of existing implantation data against current standard requirements

• Biological evaluation planning under ISO 10993-1:2025's risk-based framework

• Biocompatibility evaluation report preparation integrating implantation data with chemical characterization and toxicological risk assessment

• FDA submission support for 510(k), PMA, and De Novo applications

• Deficiency response preparation addressing FDA questions on implantation testing

With over a decade of specialized experience in medical device biocompatibility and FDA regulatory submissions, Dr. James Lyons and the JL Tox team provide the expertise needed to navigate current ISO 10993 requirements and build submissions that hold up under FDA review.

Contact JL Tox Consulting to discuss your implantation study needs:

Email: info@JLTox.com

Phone: (877) 899-6568